Search
for
Sort by
Research 721–750 of 773
- Comparative characteristics of the effectiveness of drugs for the treatment of alopecia areata in childhood
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- 870 Y27632 promotes proliferation via EGFR signaling in a newly isolated and characterized human primary sebocyte cell line
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
- Off-Label Treatment of Alopecia Areata—Retrospective Study
- Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Immunology of alopecia areata
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure
- Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Janus kinase inhibitors for alopecia areata
- The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19
- Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections
- XMU-MP-1 induces growth arrest in a model human mini-organ and antagonises cell cycle-dependent paclitaxel cytotoxicity
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- N6-methyladenosine (m6A)-circHECA from secondary hair follicle of cashmere goats: identification, regulatory network and expression regulated potentially by methylation of its host gene promoter
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Alopecia Areata: Clinical Treatment
- Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- <div>Six years of the IP Indian Journal of Clinical and Experimental Dermatology (2019-2025):&nbsp;<span style="font-size: 1rem;">A bibliometric and thematic analysis</span></div>
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review